aTyr Pharma, Inc.

AI-generated fair value estimate for this company.

Method: Net cash of $46.12M (approximately $0.47/share on 98.09M shares, from $57.4M cash less $11.3M debt) plus roughly $0.08/share of conservative risk-adjusted pipeline value for the ongoing Phase 2 and FDA-aligned Phase 3 sarcoidosis trial, plus roughly $0.03-0.05/share for the Kyorin Japan partnership option, heavily discounted.

Reasoning: aTyr Pharma is a pre-revenue biotech valued primarily off net cash per standard practice for this profile; pipeline value is heavily discounted given the original Phase 3 trial missed its overall primary endpoint, with only modest credit given for the positive subgroup data and FDA-aligned path forward.